TIDMCLIN

RNS Number : 1961R

Clinigen Group plc

03 November 2021

3rd November 2021

Issue of Equity

Clinigen Group plc (AIM: CLIN, the "Group") announces that it has made an application for the admission to trading on AIM of 338,079 ordinary shares of 0.1 pence each in the Group (the "New Ordinary Shares"). These New Ordinary Shares have been issued to satisfy share options vesting under the 2018 Clinigen Group Long-Term Incentive Plan and rank pari passu with the existing shares of the Group. Admission to trading on AIM of the New Ordinary Shares is anticipated to occur on 4 November 2021.

At admission the issued share capital of the Group will consist of 133,366,726 ordinary shares, with no shares held in treasury. The total number of voting rights in the Group will therefore be 133,366,726. This figure may be used by shareholders as the denominator to determine if they are required to notify their interests in, or a change to their interests in, the Group under the Disclosure Guidance and Transparency Rules.

-Ends-

Contact details

 
 Clinigen Group plc                               +44 (0) 1283 495010 
 Rob Fox, VP Investor Relations and Corporate     investors@clinigengroup.com 
  Development 
 
 Numis Securities Limited - Nominated Adviser     Tel: +44 (0) 20 7260 1000 
  & Joint Broker 
 James Black / Garry Levin / Freddie Barnfield    Clinigen@Numis.com 
 RBC Capital Markets - Joint Broker               Tel: +44 (0) 20 7653 4000 
 Marcus Jackson / Elliot Thomas 
 
   Consilium Strategic Communications               Tel: +44 (0) 20 3709 5700 
 Mary-Jane Elliott / Matthew Cole / Jessica       Clinigen@consilium-comms.com 
  Hodgson

Notes to Editors

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global, specialist pharmaceutical services and products platform focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time. The Group operates from sites in North America, Europe, Africa and the Asia Pacific.

Clinigen has more than 1,000 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 34 of the top 50 pharmaceutical companies; interacting with over 5,000 hospitals across more than 120 countries.

For more information on Clinigen, please visit http://www.clinigen.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEDKNBKFBDKQDK

(END) Dow Jones Newswires

November 03, 2021 04:05 ET (08:05 GMT)

Clinigen (LSE:CLIN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Clinigen Charts.
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Clinigen Charts.